Sign in
CompletedNo phase

MASTERMIND-Pneumonia Study (Also Known as Pneumonia Direct Pilot)

Key facts

Who runs it
Duke University
Where
Detroit, Pittsburgh, Royal Oak, and St Louis, United StatesSee the 4 sites
Trial code
Status
Completed
People taking part
173 people enrolled
Started
12 Apr 2024
Ended
3 Jul 2025
Type of study
Observational
Treatments tested
  • Pathogen and Host Directed testing
Record updated
27 April 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Are ≥18 years old
  • Are newly intubated for less than 48 hours and for reasons other than suspected bacterial pneumonia or suspected acute bacterial infection
  • Are expected to require intubation for at least 48 hours, per the discretion of the treating clinician
  • Are able to provide protocol-accepted consent (legally authorized representative [LAR] is acceptable)
  • Are expected to live long enough to receive a VAP diagnosis, at the discretion of the treating clinician
  • Are able to provide study-required biological samples

Who cannot take part

  • Received a lung transplant
  • Are receiving comfort care
  • Are receiving antibiotic treatment for suspected or proven active acute bacterial infection (eg, pneumonia, tracheobronchitis, sepsis)
  • Were previously enrolled in this trial
  • Are currently participating in an interventional drug or device study
  • Have known active lung cancer or metastatic disease to a lung
  • Have a witnessed or suspected aspiration event prompting the need for current, new intubation
  • Have cystic fibrosis
  • Have a current or within-the-last-30-days diagnosis of active bacterial pneumonia
  • Require long-term ventilator support
  • Have a tracheostomy tube in place

Where in United States

  • Henry Ford HospitalDetroit, United States
  • University of Pittsburgh Medical CenterPittsburgh, United States
  • Corewell (William Beaumont)Royal Oak, United States
  • Washington University School of Medicine in St. LouisSt Louis, United States

About the trial

What the trial wants to find out

The MASTERMIND-Pneumonia Study (also known as Pneumonia Direct Pilot Study) is designed to assess whether combining molecular diagnostics for bacteria and AMR markers with host-response profiling improves agreement and predictive value for the diagnosis of VAP versus an adjudicated clinical reference standard. The feasibility design is intended to inform future interventional studies that will investigate the clinical impact of combined pathogen- and host-directed testing approaches.

The group in the trial

  • Standard of Care

    There are no interventions in this study. Standard of care activities will be captured in the eCRF and samples will be collected and tested. Results will not be returned to the sites or participants.

    Treatment: Pathogen and Host Directed testing

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Pneumonia Direct Pilot
Record updated
27 April 2026